What is the role of MED12 in acute myeloid leukemia (AML)?
Best insight from top research papers
MED12 plays a crucial role in acute myeloid leukemia (AML) by being epigenetically regulated and over-expressed in specific AML subgroups, particularly the core-binding factor (CBF) subgroups like inv(16) and t(8;21) . Mutations in MED12 can lead to dysregulated CDK8 kinase activity, impacting tumorigenesis in benign and malignant tumors . Additionally, MED12 is involved in antibody class switching recombination (CSR) by activating the IgH 3’ regulatory region (3’RR) super-enhancer, essential for AID-induced DNA double strand breaks and S-S synapse formation . Furthermore, MED12 mutations are associated with enhanced immune checkpoint inhibitor (ICI) therapy responses across various cancers, indicating its potential as a predictive biomarker for ICIs in pan-cancer treatment .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
17 Jun 2022 | Not addressed in the paper. |
| Not addressed in the paper. | |
| Not addressed in the paper. | |
| MED12 over-expression in core-binding factor AML subgroups is epigenetically regulated, fostering leukemic growth. It recruits transcription factors on super-enhancers, impacting cell fate determination and oncogenesis in AML. | |
| Not addressed in the paper. |
Related Questions
What's the role of trpm8 in liver? in aml12 cell?4 answersTRPM8 plays a role in liver regeneration and hepatocyte proliferation in mice after hepatectomy. TRPM8 deficiency impairs liver regeneration and mitochondrial energy metabolism in mice. TRPM8 also contributes to the proliferation of hepatocytes via PGC1α. In the context of liver fibrosis, TRPM8 expression is upregulated in tissue samples from cirrhosis patients and fibrotic mice. TRPM8 deficiency attenuates inflammation and fibrosis progression in mice and helps alleviate symptoms of cholangiopathies. TRPM8 deficiency may exert protective effects against inflammation, cholangiopathies, and fibrosis through S100A9-HNF4α signaling. However, the role of TRPM8 in AML12 cells specifically is not mentioned in the provided abstracts.
How Nanopore sequencing play role in AML diagnosis?4 answersNanopore sequencing plays a role in the diagnosis of acute myeloid leukemia (AML) by providing a fast, cost-effective, and accurate method for classifying genomic subtypes of the disease. It allows for the generation of long-read transcripts from acute leukemia specimens, enabling the prediction of AML lineage and major molecular subtypes directly from gene expression profiles. This classification approach has shown high accuracy in distinguishing AML from other acute leukemia subtypes, with a probability of >0.8 and 100% accuracy. Additionally, nanopore sequencing can further classify AML samples into clinically actionable genomic subtypes with high accuracy. By utilizing nanopore technology for diagnostic classification, the accuracy of AML diagnosis can be improved, particularly in low-resource settings where health centers lack the tools required for accurate diagnosis.
Why is CRISPR useful in AML research?5 answersCRISPR is useful in AML research because it allows for the identification of therapeutic targets and dependencies in AML cells. High-density CRISPR screens have been used to map epigenetic regulators critical for sustaining stemness networks in AML, revealing potential new therapeutic targets. CRISPR-based genetic screens have also been used to identify AML-enriched dependencies, both in vitro and in vivo, leading to the discovery of novel therapeutic opportunities. Additionally, CRISPR/Cas9 gene editing has been used to develop allogeneic anti-CD83 CAR-T cells for the treatment of AML, potentially improving outcomes and reducing the risk of graft-versus-host disease. Overall, CRISPR technology provides a powerful tool for understanding the molecular mechanisms underlying AML and identifying potential targets for therapeutic intervention.
What are the molecular mechanisms of acute myeloid leukemia?5 answersAcute myeloid leukemia (AML) is driven by various molecular mechanisms. NUP98 fusion proteins form biomolecular condensates in AML cells, containing essential transcriptional activators that induce oncogenic gene expression programs. Gain-of-function mutations of isocitrate dehydrogenases 1/2 (IDH1/2) play crucial roles in AML development and progression. Resistance to IDH1/2 inhibitors, such as ivosidenib and enasidenib, is a major problem in targeted therapies for IDH-mutant AML. The expression of the EVI1 transcription factor is associated with poor outcome in AML, even without rearrangements of the EVI1 locus. Genomic abnormalities, including BCR::ABL1 kinase domain mutations, contribute to TKI resistance in CML. The expansion of Evi1-expressing hematopoietic stem and progenitor cells (HSPC) by exogenous factors can result in a more aggressive MLL-AF9-driven AML. These findings provide insights into the molecular mechanisms underlying AML and CML, which can guide the development of targeted therapies.
Why is acute myeloid leukemia relevant?4 answersAcute myeloid leukemia (AML) is a complex and heterogenous hematological malignancy caused by mutations in myeloid differentiation and proliferation. It is clinically relevant due to its variable response to therapy and long-term outcomes, which are influenced by chromosomal and molecular aberrations. AML is diagnosed through various genetic approaches such as morphology study, histology, immunophenotyping, cytogenetics, fluorescent in situ hybridization, and molecular genetic testing. Metabolomics, the global profiling of small molecules, has emerged as an important tool for studying the metabolic dependency of cancer cells, including AML. Metabolic reprogramming is not only a manifestation of AML but also clinically relevant for diagnosis, risk stratification, and targeted drug development. Understanding the genetic and molecular aspects of AML is crucial for accurate diagnosis, prognosis assessment, and defining appropriate therapy strategies.
What are the molecular mechanisms of acute myeloid leukaemia?4 answersAcute myeloid leukaemia (AML) is a malignant disorder of the bone marrow characterized by clonal expansion and differentiation arrest of myeloid progenitor cells. AML is a highly heterogeneous disease with patterns of both divergent and convergent molecular evolution within the leukemic compartment. The pathogenesis of AML often involves mutations in proliferation/survival mechanisms and differentiation pathways. Comprehensive cataloguing of the AML genome has revealed a high frequency of mutations and deletions in epigenetic factors, which are linked to treatment resistance and poor patient outcome. Wnt signaling is upregulated in AML through various mechanisms and is necessary for the maintenance of leukemic stem cells. Targeting Wnt signaling is being explored as a potential therapeutic approach for AML.